

RESULTS OF GENERAL MEETING

Melbourne, Australia – 24 April 2025: Percheron Therapeutics Limited (ASX:PER or “the Company”) is pleased to advise the results of today’s General Meeting of shareholders.

In accordance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act, the results of the General Meeting are set out in the attached report and include a summary of the poll voting results by proxies on each resolution considered at the General Meeting.

All resolutions to be voted on at the meeting were decided on a poll.

More than 450 shareholders voted or directed a proxy in the meeting. Of these, over 90% voted in favour of retaining the current Board and against the directors nominated by Powerhouse Ventures Limited.

” We are immensely thankful to shareholders for their emphatic support,” commented Dr Charmaine Gittleston, Chair of the Board at Percheron. “It is now time to put these disputes behind us and focus our entire efforts on the vital task of restoring value for shareholders. The team has been working hard to this end over the past several months, and we look forward to sharing updates on progress.”

~ ENDS ~

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTCQB: PERCF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The company’s lead program is avicursen (ATL1102), an antisense oligonucleotide targeting the CD49d receptor, which has been investigated in a range of inflammatory conditions, including multiple sclerosis and Duchenne muscular dystrophy. For more information, please contact info@PercheronTx.com.

This announcement has been authorized for release to the Australian Securities Exchange by the Board of Directors.

Percheron Therapeutics Limited
General Meeting
Thursday, 24 April 2025
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

| Resolution details | | Instructions given to validly appointed proxies (as at proxy close) | | | | Number of votes cast on the poll (where applicable) | | | Resolution Result | If s250U applies |
|---|--------------------|--|-----------------------|-----------------------|-----------|--|------------------------------|----------------|--------------------------|---------------------|
| Resolution | Resolution Type | For | Against | Proxy's Discretion | Abstain | For | Against | Abstain* | Carried / Not Carried | |
| 1. Removal of current Director - Dr Charmaine Gittleson | Ordinary | 165,987,954 28.02% | 426,475,066 71.98% | 0 0.00% | 0 | 166,133,863 28.03% 41 | 426,475,066 71.97% 419 | 0 0 | Not Carried | N/A |
| 2. Removal of current Director - Dr James Garner | Ordinary | 157,127,974 26.52% | 435,335,046 73.48% | 0 0.00% | 0 | 157,273,883 26.54% 41 | 435,335,046 73.46% 419 | 0 0 | Not Carried | N/A |
| 3. Removal of current Director - Dr Ben Gill Price | Ordinary | 168,487,954 28.44% | 423,975,066 71.56% | 0 0.00% | 0 | 168,633,863 28.46% 42 | 423,975,066 71.54% 418 | 0 0 | Not Carried | N/A |
| 4. Appointment of new Director - Mr Doron Eldar | Ordinary | 161,783,596 27.50% | 426,475,066 72.50% | 0 0.00% | 4,204,358 | 161,929,505 27.52% 39 | 426,475,066 72.48% 419 | 4,204,358 2 | Not Carried | N/A |
| 5. Appointment of new Director - Mr Julian Chick | Ordinary | 161,783,596 27.50% | 426,475,066 72.50% | 0 0.00% | 4,204,358 | 161,929,505 27.52% 39 | 426,475,066 72.48% 419 | 4,204,358 2 | Not Carried | N/A |
| 6. Appointment of new Director - Mr Richard Hamersley | Ordinary | 161,783,596 27.50% | 426,475,066 72.50% | 0 0.00% | 4,204,358 | 161,929,505 27.52% 39 | 426,475,066 72.48% 419 | 4,204,358 2 | Not Carried | N/A |

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.